Company Newron Pharmaceuticals SpA CBOE EUROPE EQUITIES

0QOI

IT0004147952

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Biopharmaceuticals

Inactive Instrument

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^CHF	-

13/05	Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients	CI
30/04	Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	CI

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinsonâs disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

CHF in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Drugs 100.0 %	6	100.0 %	9	100.0 %	+43.85%

CHF in Million	2022	Weight	2023	Weight	Delta
Italy & United States 100.0 %	6	100.0 %	9	100.0 %	+43.85%

Managers	Title	Age	Since
Stefan Weber CEO	Chief Executive Officer	60	15/12/15
Luca Benatti FOU	Founder	63	01/98/01
Roberto Galli DFI	Director of Finance/CFO	-	01/02/01
Filippo Moriggia COO	Chief Operating Officer	-	01/16/01
Ravi Anand CTO	Chief Tech/Sci/R&D Officer	67	01/05/01
Laura Faravelli PRN	Corporate Officer/Principal	-	01/19/01
Dennis Dionne PRN	Corporate Officer/Principal	-	01/15/01

Members of the board	Title	Age	Since
Patrick J. Langlois BRD	Director/Board Member	78	01/08/01
Luca Benatti FOU	Founder	63	01/98/01
Ulrich Köstlin CHM	Chairman	71	01/13/01
Stefan Weber CEO	Chief Executive Officer	60	15/12/15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,631,834	16,874,414 ( 90.57 %)	0	90.57 %

Name	Equities	%	Valuation
Heights Capital Management, Inc. 4.025 %	750,000	4.025 %	8 M CHF
Tobias Scherer 3.542 %	660,000	3.542 %	7 M CHF
Gefim SpA 2.990 %	557,092	2.990 %	6 M CHF
DWS CH AG 0.0920 %	17,134	0.0920 %	189 924 CHF
Baloise Asset Management AG 0.0905 %	16,858	0.0905 %	186 865 CHF
amandea Vermögensverwaltung AG 0.0349 %	6,500	0.0349 %	72 050 CHF
Migros Bank AG 0.0194 %	3,619	0.0194 %	40 115 CHF
State Street Global Advisors France SA 0.0132 %	2,463	0.0132 %	27 301 CHF
LLB Asset Management AG 0.007927 %	1,477	0.007927 %	16 372 CHF
European Investment Bank 0.000000 %	0	0.000000 %	- CHF

Newron Pharmaceuticals SpA

via Antonio Meucci 3

20091, Bresso

+39 02 610 3461

https://www.newron.com/

address Newron Pharmaceuticals SpA(0QOI)

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+2.87%	9.42TCr
SAMSUNG BIOLOGICS CO.,LTD.	-4.08%	3.78TCr
BIOGEN INC.	-13.67%	3.25TCr
UCB	+73.38%	2.78TCr
BIOMARIN PHARMACEUTICAL INC.	-11.63%	1.61TCr
INCYTE CORPORATION	-0.67%	1.42TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.67%	1.14TCr
ALTEOGEN INC.	+190.36%	1.11TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-52.61%	908.81Cr

Biopharmaceuticals